中医药联合肿瘤靶向药物治疗非小细胞肺癌的研究进展

Research progress of Chinese medicine combined with tumor-targeted drugs in the treatment of non-small cell lung cancer

近年来肺癌的发生率和死亡率急剧上升,在各城市中居首位。肺癌治疗需要根据患者的机体状况、细胞学、肿瘤、病理学类型等多方面依据,采取多学科综合治疗模式,注重个体化治疗。非小细胞肺癌是肺癌最常见的类型,也是肺癌死亡率较高的一种疾病之一,靶向治疗是非小细胞肺癌的首选治疗方案。随着靶向药物使用范围的扩大,其耐药性及不良反应的出现减缓了治疗进程。目前中医药联合肿瘤靶向药物治疗非小细胞肺癌成为研究热点,相关研究表明中医药联合肿瘤靶向药物可以提高生存率和生活质量,降低不良反应以及延缓患者产生耐药的时间。本文将进一步对中医药联合肿瘤靶向药物治疗在非小细胞肺癌领域的研究进行总结归纳,以期为中医药联合肿瘤靶向药物治疗提供理论依据,为防止耐药和临床治疗提供理论依据。

In recent years,the incidence and mortality of lung cancer have risen sharply,ranking first among cities.The treatment of lung cancer needs to adopt a multi-disciplinary comprehensive treatment model based on the patient′s physical condition,cytology,tumor,pathological type,etc.,and focus on individualized treatment.Non-small cell lung cancer is the most common type of lung cancer,and it is also one of the diseases with high mortality of lung cancer,Targeted therapy is the preferred treatment option for non-small cell lung cancer.With the expansion of the use of targeted drugs,the emergence of drug resistance and adverse reactions slowed the treatment process.At present,Chinese medicine combined with tumor-targeted drugs in the treatment of non-small cell lung cancer has become a research hotspot.Relevant studies have shown that Chinese medicine combined with tumor-targeted drugs can improve survival rate and quality of life,reduce adverse reactions and delay the time for patients to develop drug resistance.This article will further summarize the research of Chinese medicine combined with tumor-targeted drug therapy in the field of non-small cell lung cancer,in order to provide a theoretical basis for Chinese medicine combined with tumor-targeted drug therapy,and provide a theoretical basis for prevention of drug resistance and clinical treatment.